Pharmacokinetics and antidepressant activity of fluoxetine in transgenic mice with elevated serum alpha-1-acid glycoprotein levels

Drug Metabolism and Disposition

Volumn 26, Issue 1, 1998, Pages 20-24

  Holladay, John W ^a   Dewey, Michael J ^b   Yoo, Sun D ^b  

^a HOWARD UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; FLUOXETINE; NORFLUOXETINE; OROSOMUCOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DEMETHYLATION; DEPRESSION; DRUG DISPOSITION; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; LIVER METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRAIN; BRAIN CHEMISTRY; FEMALE; FLUOXETINE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; OROSOMUCOID; SWIMMING; TIME FACTORS;

EID: 0031918923     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Abramson FP and Lutz MP (1986) The kinetics of induction by rifampin of alpha-1-acid glycoprotein and antipyrine clearance in the dog. Drug Metab Dispos 14:46-51.
2. Altamura A, Moro AR and Percudani M (1994) Clinical pharmacokinetics of fluoxetine. J Pharmacokinet 26:201-214.
3. Aronoff GR, Bergstrom RF, Pottratz ST, Sloan RS, Wolen RL and Lemberger L (1984) Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther 36:138-144.
4. Belpaire FM, Bogaert MG, Mugabo P and Rosseel MT (1986) Binding to serum alpha-1-acid glycoprotein and effect of beta-adrenoceptor antagonists in rats with inflammation. Br J Pharmacol 88:697-705.
5. Benfield P, Hell RC and Lewis SP (1986) Fluoxetine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 32:481-508.
6. Bergstrom RF, Peyton AL and Lemberger L (1992) Quantitation and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 51:239-248.
7. Caccia S, Cappi M, Fracasso C and Garattini S (1990) Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology 100:509-514.
8. Cesana R, Ceci A, Ciprandi C and Borsini F (1993) Mesulergine antagonism towards the fluoxetine anti-immobility effect in the forced swimming test in mice. J Pharm Pharmacol 45:473-475.
9. Chiang J and Øie S (1990) Pharmacologic activity of prazosin is decreased by alpha-1-acid glycoprotein in vivo. J Pharmacol Exp Ther 254:324-329.
10. DeRick DE, Belpaire FM and Bogaert MG (1987) Influence of enhanced alpha-1-acid glycoprotein concentration on protein binding, pharmacokinetics and antiarrthymic effect of lidocaine in the dog. J Pharmacol Exp Ther 241:289-293.
11. Dewey MJ, Rheaume C, Berger FG and Baumann H (1990) Inducible and tissue specific expression of rat alpha-1-acid glycoprotein in transgenic mice. J Immunol 144:4392-4398.
12. El-Yazigi K, Chaleby A, Gad and Raines DA (1995) Steady state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. J Clin Pharmacol 35:17-21.
13. Fuller RW and Snoody HD (1993) Drug concentrations in mouse brain at pharmacologically active doses of fluoxetine enantiomers. Biochem Pharmacol 45:2355-2358.
14. Griebel G, Blanchard DC, Agnes RS and Blanchard RJ (1995) Differential modulation of antipredator defensive behavior in swiss-webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology 120:57-66.
15. Holladay JW, Dewey MJ and Yoo SD (1996) Steady state kinetics of imipramine in transgenic mice with elevated serum AAG levels. Pharmacol Res 13:1313-1316.
16. Huang J and Øie S (1985) Influence of serum protein binding on hepatic clearance of S-disopyramide in the rabbit. J Pharm Pharmacol 37:471-475.
17. Kelly MW, Perry PJ, Holstad SG and Garvey MJ (1989) Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther Drug Monit 11:165-170.
18. Kremer JMH, Wilting J and Janssen LMH (1988) Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 40:1-14.
19. Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG and Aronoff GR (1985) Fluoxetine: Clinical pharmacology and physiologic disposition. J Clin Psychiatry 46:14-19.
20. Luzier A and Morse GD (1993) Intravascular distribution of zidovudine: Role of plasma proteins and whole blood components. Antiviral Res 21:267-280.
21. Porsolt RD, Bertin A and Jalfre M (1978) "Behavioural despair" in rats and mice: Strain differences and the effects of imipramine. Eur J Pharmacol 51:291-294.
22. Wilkinson GR and Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.
23. Yasuhara M, Fugiwara J, Kitade S, Katayama H, Okumura K and Hori R (1985) Effect of altered plasma protein binding on pharmacokinetics and pharmacodynamics of propranolol in rats after surgery: Role of alpha-1-acid glycoprotein. J Pharmacol Exp Ther 235:513-520.
24. Yoo SD, Holladay JW, Fincher TK, Baumann H and Dewey MJ (1996) Altered disposition and antidepressant activity of imipramine in transgenic mice with elevated serum alpha-1-acid glycoprotein. J Pharmacol Exp Ther 276:918-922.